I was watching the “Morning Joe” talk show this morning — well, not really watching; it was more like background noise while I worked on a few things — when something caught my eye (or, more accurately, my ear). The hosts were introducing a guest who’d just…

“’Hang on a sec, hon,’ I called to my husband in the car, at the airport, and again on the plane. ‘I want to get a good shot. I’m sure something from this trip will work its way into my next column.’” That’s how I started my column one…

The European Medicines Agency (EMA) has granted XTMAB-16, Xentria‘s investigational antibody therapy, orphan drug designation for sarcoidosis. The status is intended to help speed the development of therapies that would fulfill an unmet health need for people with life-threatening or chronically debilitating rare diseases, which are defined as…

Bracelets with messages meant just to cheer me, Wireless earbuds when anyone’s near me, Cute comfy PJs without a drawstring, These are a few of my favorite things. The holidays are upon us, and while that should be a time of joy and celebration, of love and…

EFZO-FIT, a Phase 3 trial that’s testing treatment candidate efzofitimod in people with pulmonary sarcoidosis, is continuing  following a pre-planned interim safety review, with enrollment expected to finish in the first half of 2024. A data safety and monitoring board (DSMB) examined the trial’s available safety and tolerability…

Ten years ago this month, I was devastated to leave a job I loved — one I thought would be the beginning of my career, not the end of it. It was a dream job, so losing it was a nightmare. I’d practically done the job for free already. I…

It is with deep sadness that we inform the Sarcoidosis News community of the passing of our friend and gifted columnist Charlton Harris on Aug. 25, 2023, only a few days before the publication of his final column. Charlton visiting…

This year’s Global Virtual Sarcoidosis Summit, hosted by the Foundation for Sarcoidosis Research (FSR), is bringing together the sarcoidosis community under the theme “Find Your Community, Find Your Life.” Those interested in taking part in the summit, happening virtually from Nov. 3 to 5, can register…

Higher doses of the investigational therapy efzofitimod significantly reduced relapse rates after a dose of a corticosteroid was reduced in people with pulmonary sarcoidosis, according to a new, pooled analysis of Phase 1b/2a trial data. The first-in-class immunomodulatory therapy, developed by aTyr Pharma, also significantly improved lung…

How do I know that my hip is getting better? My back is hurting more. I know that sounds like a bad joke, but it really falls into the category of “funny ’cause it’s true.” It’s not actually funny, but laughter is a great coping mechanism. Sometimes I can’t tell…